Higher Levels of Anti-CA15.3 and Anti-CA125 Linked to Increased Risk for Mucinous Epithelial Ovarian CancerOctober 12, 2018
Researchers used the EPIC Cohort to identify whether anti-CA125 and anti-CA15.3 antibodies alone or in combination with antigens may determine epithelial ovarian cancer risk.
Although ovarian cancer risk may be reduced with regular use of low-dose aspirin, the use of nonaspirin analgesics may increase the risk of ovarian cancer among long-term, high-quantity users.
Women with ovarian or endometrial cancer who adhere to a ketogenic diet may benefit from a selective loss of fat mass and a reduction in fasting serum insulin, while still retaining lean mass.
Combined hormonal contraception use tied to lower risk; risk down with increasing duration of use.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Quantitative Image Marker Beneficial for Identifying Response to Postsurgical Chemotherapy in Ovarian CancerSeptember 10, 2018
Researchers identify a quantitative image marker that may be beneficial in predicting response to postsurgical chemotherapy in advanced-stage ovarian cancer.
Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian CancerSeptember 10, 2018
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
A Phase 1 study in healthy volunteers showed a favorable safety profile with no serious adverse events.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
In a multicenter study, researchers used high-quality ultrasound imaging to identify characteristics of pure ovarian clear cell carcinoma.
No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction.
The ENGOT-OV16/NOVA trial showed improvements in progression-free survival in patients with ovarian cancer with and without the germline BRCA mutation.
Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.
Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer.
An analysis of population data on cancer incidence, survival, and mortality revealed that early interventions and improvements to treatments contributed to a 26% decline in cancer deaths from 1991 to 2015.
First-line chemotherapy in combination with bevacizumab, compared with chemotherapy alone, may benefit patients with ovarian cancer and elevated neutrophil-to-lymphocyte ratios.
No significant difference was identified in combination CA125/CEA ratio vs CEA alone in distinguishing ovarian neoplasms from ovarian metastases.
Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).
Mirvetuximuab soravtansine uses a humanized FRα-binding antibody to target antibody-drug conjugates specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.
A prophylactic, graded, extended infusion of carboplatin, compared with a shorter, standard infusion, is not associated with a reduced rate of HSRs in women with recurrent ovarian cancer.
In a case study, olaparib was found to induce folate deficiency in most patients with relapsed ovarian cancer. Researchers discuss the significance of this adverse effect and how it was managed.
For patients with platinum-sensitive recurrent ovarian cancer, trabectedin plus PLD may be beneficial.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Advanced Ovarian Cancer Survival Rates Longer After Primary Cytoreductive Surgery Compared With Neoadjuvant ChemotherapyApril 12, 2018
Researchers found a superior survival rate in patients who received primary cytoreductive surgery as opposed to neoadjuvant chemotherapy for stage IIIC and IV high-grade serous ovarian carcinoma.
The FDA has approved Rubraca, a poly (ADP-ribose) polymerase inhibitor, to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Genetic mutations assays using PapSEEK may facilitate the detection of certain cancers using fluids from Pap tests.
Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.
For patients with ovarian cancer taking pegylated liposomal doxorubicin who have hand-foot syndrome, frozen gloves and socks is a safe method of treatment.
The incidence of ovarian cancer was not related to metformin or statin usage among women with type 2 diabetes.
The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.